https://orcid.org/0000-0002-8661-9597
Figures
Abstract
Background
Little is known about whether people who use both tobacco and cannabis (co-use) are more or less likely to have mental health disorders than single substance users or non-users. We aimed to examine associations between use of tobacco and/or cannabis with anxiety and depression.
Methods
We analyzed data from the COVID-19 Citizen Science Study, a digital cohort study, collected via online surveys during 2020–2022 from a convenience sample of 53,843 US adults (≥ 18 years old) nationwide. Past 30-day use of tobacco and cannabis was self-reported at baseline and categorized into four exclusive patterns: tobacco-only use, cannabis-only use, co-use of both substances, and non-use. Anxiety and depression were repeatedly measured in monthly surveys. To account for multiple assessments of mental health outcomes within a participant, we used Generalized Estimating Equations to examine associations between the patterns of tobacco and cannabis use with each outcome.
Results
In the total sample (mean age 51.0 years old, 67.9% female), 4.9% reported tobacco-only use, 6.9% cannabis-only use, 1.6% co-use, and 86.6% non-use. Proportions of reporting anxiety and depression were highest for the co-use group (26.5% and 28.3%, respectively) and lowest for the non-use group (10.6% and 11.2%, respectively). Compared to non-use, the adjusted odds of mental health disorders were highest for co-use (Anxiety: OR = 1.89, 95%CI = 1.64–2.18; Depression: OR = 1.77, 95%CI = 1.46–2.16), followed by cannabis-only use, and tobacco-only use. Compared to tobacco-only use, co-use (OR = 1.35, 95%CI = 1.08–1.69) and cannabis-only use (OR = 1.17, 95%CI = 1.00–1.37) were associated with higher adjusted odds for anxiety, but not for depression. Daily use (vs. non-daily use) of cigarettes, e-cigarettes, and cannabis were associated with higher adjusted odds for anxiety and depression.
Citation: Nguyen N, Peyser ND, Olgin JE, Pletcher MJ, Beatty AL, Modrow MF, et al. (2023) Associations between tobacco and cannabis use and anxiety and depression among adults in the United States: Findings from the COVID-19 citizen science study. PLoS ONE 18(9): e0289058. https://doi.org/10.1371/journal.pone.0289058
Editor: Yuan-Pang Wang, University of Sao Paulo, School of Medicine, BRAZIL
Received: January 31, 2023; Accepted: July 10, 2023; Published: September 13, 2023
Copyright: © 2023 Nguyen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting information files.
Funding: NN is supported by the California Tobacco-Related Disease Research Program (grants T31FT1564 and T32KT5071) and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF Clinical and Translational Science Institute (grant UL1 TR001872-06). The Eureka Research Platform was supported by grant 5U2CEB021881 from NIH to GM, JO, and MP. The COVID-19 Citizen Science Study is supported by Patient-Centered Outcomes Research Institute contract COVID-2020C2-10761 to GM, JO, and MP; the Bill and Melinda Gates Foundation contract INV-017206 to GM, JO, and MP, and grants 75N91020C00039 from NIH/NCI and 3U2CEB021881-05S1 from NIH/NIBIB to GM, JO, and MP. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Tobacco and cannabis are among the most commonly used substances worldwide. In the U.S., 22.1% of adults reported using tobacco and 12.4% using cannabis in the past month in 2020 [1]. Co-use of tobacco and cannabis (defined in this study as concurrently using both substances in the past month) is also prevalent with 33% of people who use tobacco also reporting using cannabis in the past month [2,3]. Amid the expanding legalization of cannabis nationwide, use of cannabis and co-use of tobacco and cannabis have been increasing recently [3,4]. Studies showed that cannabis use increased over time and is 2–10 times more common among those with, versus without, cigarette smoking [3]. These trends raise concerns about unknown harms related to cannabis use in general and co-use of tobacco and cannabis in particular [5]. Co-use may increase exposure to toxicants and pose additive health risks [6,7]. It is also associated with increased risk for nicotine and cannabis dependence and poorer cessation outcomes for both tobacco and cannabis [8–10]. However, understanding of the association between co-use and health remains limited [5,11].
Use of either tobacco or cannabis are related to poor mental health [12–14] with the mixed literature on the direction of these relationships [14,15]. The extant work found that regular nicotine use is associated with increased risk of the onset and persistence of depression and anxiety [16–18]. Conversely, people with anxiety and depression are more likely to use cigarettes and other tobacco products (e.g., e-cigarettes, hookah) than those without these mental health disorders [19–21]. Current evidence regarding the association between cannabis and mental health is similar [13,14]. Cannabis use is two to three times higher among individuals with anxiety or depression compared with those without these conditions [22–24]. Also, cannabis use is a risk factor for the development of poor mental health and regular use may worsen depressive symptoms [25,26]. Previous studies have shown that mental health disorders are associated with heavy use and dependence of nicotine and cannabis as well as a decreased likelihood of successful cessation [27,28]. Thus, measuring mental health among people who do and do not use tobacco and/or cannabis will provide treatment implications for both mental health disorders and substance use cessation.
To date, previous research has predominantly examined the association of mental health with use of either tobacco or cannabis. Lacking are studies examining the association between co-use of both substances and mental health. The important gap to address is that whether people who use both substances are more or less likely to have mental health disorders than those who use single substances or neither of these substances. A study in the UK showed that people who used both tobacco and cannabis reported the highest prevalence of mental health treatment compared to those using single substances or not using these substances [29]. Likewise, the 2020 International Tobacco Control Survey found that co-use of tobacco and cannabis is associated with higher odds of having depressive symptoms compared to use of cigarette only among adults who smoked cigarettes in four countries (US, Canada, Australia, England) [30]. Research on co-use of tobacco and cannabis and mental health in US adult samples remains scarce. A study from a representative sample of US adults found that people with co-occurring cannabis use disorders and nicotine dependence were more likely to report psychiatric diagnoses and psychosocial problems than those with cannabis use disorders only or nicotine dependence only [31]. This study, however, collected data in 2004–2005. Given the changing product and policy landscape related to tobacco and cannabis in the US (e.g., emerging vaporized products, increasing cannabis legalization), more recent data on co-use and mental health are warranted. In addition, there has been a concerning rise in substance use and mental health problems related to social isolation and stressors during the COVID-19 pandemic. However, emerging evidence indicated mixed impacts of the pandemic with documenting both increases and decreases in substance use and mental health issues across samples. To inform efforts aimed at promoting public health well-being, it is more important than ever to address the association between use of tobacco and cannabis with mental health.
To address this gap, we analyzed a large dataset from an online cohort of US adults collected during 2020–2022, the COVID-19 Citizen Science Study (CSS) [32], leveraging recent substance exposures and previously validated mental health instruments. We aimed to examine the association between four exclusive patterns of tobacco and cannabis use (i.e., tobacco-only use, cannabis-only use, co-use of both tobacco and cannabis, and non-use) and mental health disorders (i.e., anxiety and depression). We hypothesized that co-use would be associated with higher odds of mental health disorders than use of tobacco or cannabis only and non-use.
Materials and methods
Study design and participants
This study analyzed data from the CCS study, a longitudinal cohort study hosted on the Eureka research digital platform (https://covid19.eurekaplatform.org/) [32]. The CCS study was launched in March 2020 and aimed to generate knowledge about long-term consequences of the COVID-19 pandemic based on participant-reported symptoms, behaviors, and disease occurrence. Study enrollment and follow-up are ongoing, without prespecified enrollment targets or end dates for enrollment or completion. Participation is remote, without geographic restriction. However, most participants are in the US and the participation from other countries is very low (<1%). Thus, the current study focused on only participants in the US.
This entirely digital study is hosted on Eureka, a digital research platform that produces mobile applications for clinical research built by investigators and developers at the University of California, San Francisco (UCSF). The Eureka platform is available to anyone who wants to conduct medical or health-related research, including university or other non-profit investigators, industry investigators or others. The app’s elements (e.g., electronic consent, surveys, and feedback) can be customized for individual studies. In January 2021, a web version of the CCS study was launched to enable participation options for people without a mobile phone or with concerns about downloading an app.
Using a convenience sampling method, participants were recruited through multiple channels, including email invitations to participants in other studies using the Eureka platform, press releases, word-of- mouth, social media sharing, and recruitment through partner organizations nationwide. Participants must be 18 years or older, agree to participate in English, provide consent, and register for a Eureka account. Participants were asked to complete baseline, daily, weekly, and monthly surveys about demographics, medical conditions, medications, and behaviors through the study app or website. Use of tobacco and cannabis was measured only once at baseline, while mental health was measured repeatedly in monthly surveys. There were no monetary incentives for participation in the study. Retention strategies include daily notifications, data visualizations, and intermittent study update blog posts. More details about the study procedures have been described elsewhere [32].
For this analysis, we included data collected between March 2020 (when the CCS study started) and April 2022 (the latest date when the analysis was conducted). Of 87,984 US participants who completed the baseline survey and provided data on tobacco and cannabis use, 53,843 participants (response rate of 61.2%) who completed at least one monthly survey on mental health were included in this analysis. The study duration for the participants ranged from 1–25 months, with an average length of follow-up of 8.5 ± 6.6 months. Results are reported in accordance with Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.
Ethical considerations
All participants provided informed written consent via a dedicated research mobile application to participate in the study. The CCS study was approved by the UCSF Institutional Review Board (IRB #17–21879).
Measures
Mental health outcomes (Anxiety and Depression).
Participants were asked about their mental health repeatedly in monthly surveys, and thus, there were multiple assessments of mental health outcomes nested within a participant. While anxiety and depression symptoms frequently co-occur, they have differing but independent effects on functional impairment and disability [33]. Thus, we measured anxiety and depression separately using validated instruments.
Anxiety was measured by the 7-item Generalized Anxiety Disorder scale (GAD-7), a brief and validated screening measure for anxiety symptoms used in both clinical and community samples [33]. The GAD-7 captures the frequency (from 0-“Not at all” to 3-“Nearly every day”) of the seven symptom criteria for GAD over the past two weeks. Numeric responses to these questions were summed (range of 0–21). A cutoff of 10 or greater was used to dichotomize participants into having generalized anxiety disorder per recommended scoring guidelines [33].
Depression was measured by the 8-item Patient Health Questionnaire (PHQ-8), a brief and validated screening tool for a major depression episode within the past two weeks [34]. Responses for each item range from 0-“Not at all” to 3-“Nearly every day” with a total score with a range of 0–24. A score of 10 or greater was considered as having depression per recommended scoring guidelines [34].
Independent variable (Patterns of tobacco and cannabis use).
Use of tobacco and use of cannabis were reported separately in the baseline survey. Participants reported number of days they had used each tobacco product (i.e., cigarettes, e-cigarettes, and other combustible tobacco products like cigars/cigarillos) and number of days they had used any combustible or vaporized cannabis products during the past 30 days. Those reporting 0 days were classified as non-use of tobacco or cannabis. Those reporting 30 days were classified as daily use of a product. Based on their responses, participants were categorized into four groups: tobacco-only use, cannabis-only use, co-use (using both substances in the past 30 days), and non-use of either substance. These groups were created to investigate any potential independent effects of single substance use and joint effects of co-use on mental health disorders.
Covariates.
Demographic characteristics and other covariates were collected at baseline. Age at registration was self-reported. Sex assigned at birth was self-reported as male and female. Gender identity was dichotomized into “cisgender” (i.e., man, woman) and “transgender and non-binary gender” (i.e., transgender, genderqueer, and other). Race and ethnicity were measured by combining two items: race (White, Black, Asian, Hawaiian/Pacific Islander, American Indian/Alaskan Native, or More than one race) and ethnicity (Hispanic or not). Responses were categorized into Hispanic, non-Hispanic White, non-Hispanic Asian, non-Hispanic Black, and non-Hispanic Other. Participants reported educational attainment in categories; the variable was recoded into “High school or less,” “Some college or college graduate,” “Postgraduate,” and “Other/Unknown.” Subjective social status was measured by the MacArthur Scale using a 1–10 stepladder with higher score indicating one’s higher perceived status in the social hierarchy [35]. Participants were also asked, “On average, how often have you exercised (enough to breathe heavily and/or sweat) over the past year?” with answer options ranging from “Never of rarely” to “4 or more times a week.” Participants also reported number of alcohol drinks they consumed in the past week. Physical activity and alcohol use were coded as continuous variables, corresponding to greater frequency of physical activity and alcohol consumption.
Statistical analysis
Data were analyzed using STATA 15.0 (StataCorp LLC, College Station, TX, US). Participant characteristics were summarized for the total sample and for each pattern of tobacco and cannabis use. ANOVA tests were used to compare means for continuous variables across patterns of tobacco and cannabis use, nonparametric median tests were used to compare medians for non-normally distributed variables, and chi-square tests were used to compare proportions for categorical variables.
To examine the associations between the patterns of tobacco and cannabis use (a categorical independent variable) and mental health outcomes (the binary outcomes), we fit Generalized Estimating Equations (GEE) models to account for the nesting of multiple monthly assessments of anxiety and depression within each participant [36]. Participants with any number of either mental health assessment (as long as at least one was completed) were included in these analyses, with incorporation of every such assessment completed for each individual. For each mental health outcome, we computed post-estimation contrasts to compare odds of the outcome across six pairwise comparisons among patterns of tobacco and cannabis use, using the Bonferroni method to adjust for multiple comparisons. We first used non-use as a reference group for patterns of tobacco and cannabis use. We then assessed the reference group as tobacco-only use or cannabis-only use in order to compare co-use with single-substance use. To further examine the associations between frequency of tobacco and cannabis use and the outcomes, we fit another GEE model for each outcome with daily use of cigarettes, e-cigarettes, other combustible tobacco products, and cannabis. All models accounted for demographic variables, alcohol consumption, and physical activity as these factors were associated with mental health in previous studies [37,38]. Variance inflation factors were less than 2 for all analyses, indicating that multicollinearity was not an issue. All tests were two-tailed with a significance level of α less than 0.05.
We also conducted several sensitivity analyses. First, we ran linear mixed-effects models for continuous mental health outcomes (i.e., GAD-7 and PHQ-8 scores) with the four patterns of tobacco and cannabis use. We then checked dose-response relationships by running linear mixed-effects models with continuous independent variables for tobacco and cannabis use (i.e., number of days using tobacco and cannabis) and continuous mental health outcomes (i.e., GAD-7 and PHQ-8 scores).
Results
Participant characteristics
Participants’ baseline characteristics are described in Table 1. The participants had a mean age of 51.0 ± 15.2 (SD) years old. The majority were female (67.9%), non-Hispanic White (81.8%), identified as cisgender (98.6%), and had education attainment of some college or college graduate (51.4%). The mean score of subjective social status was 6.9 ± 1.6 (SD). More than half reported doing exercise more than once a week in the past year. Participants reported having a median of 1 drink of alcohol (IQR = 0–5) in the past week. Regarding use patterns of tobacco and cannabis, 2,617 participants (4.9% of the sample) reported tobacco-only use; 3,702 (6.9%) reported cannabis-only use, 889 (1.6%) reported co-use, and 46,633 (86.6%) reported non-use. In terms of mental health, 6428 (11.9%) and 6794 (12.6%) participants reported experiencing anxiety and depression in at least one monthly survey, respectively. Proportions of self-reported anxiety and depression were highest among those who reported co-use of tobacco and cannabis (26.5% and 28.3%, respectively) and lowest among those who reported non-use (10.6% and 11.2%, respectively).
Association between patterns of tobacco and cannabis use and mental health outcomes.
Results from the GEE models are presented in Table 2. Compared to non-use, the adjusted odds of mental health disorders were highest for co-use (Anxiety: OR 1.89, 95% CI 1.64–2.18; Depression: OR 1.77, 95% CI 1.46–2.16), followed by cannabis-only use (Anxiety: OR 1.65, 95% CI 1.52–1.78; Depression: OR 1.67, 95% CI 1.50–1.86), and tobacco-only use (Anxiety: OR 1.40, 95% CI 1.28–1.54; Depression: OR 1.45, 95% CI 1.28–1.64).
Compared to tobacco-only use, co-use was associated with higher adjusted odds for anxiety (OR 1.35, 95% CI 1.08–1.69), but not for depression (OR 1.22, 95% CI 0.98–1.53). Likewise, cannabis-only use was associated with higher adjusted odds for anxiety (OR 1.17, 95% CI 1.00–1.37), but not for depression (OR 1.15, 95% CI 0.98–1.35) compared to tobacco-only use. However, there were no significant differences between co-use and cannabis-only use (Anxiety: OR 1.15, 95% CI 0.93–1.42; Depression: OR 1.06, 95% CI 0.86–1.32).
Several covariates were significantly associated with mental health outcomes. Young adults aged 18–29 years (vs. older age), females (vs. males), and transgender and non-binary gender participants (vs. cisgender peers) had higher odds of reporting anxiety and depression. Conversely, covariates associated with lower odds of having mental health disorders were being non-Hispanic Black, non-Hispanic Asian, or non-Hispanic Other (vs. non-Hispanic White), perceiving higher subjective social status, or having greater frequency of physical activity. Reporting greater alcohol consumption was associated with slightly higher odds of anxiety, but not depression. Across the study years, the odds of reporting anxiety and depression were lower in 2021 and 2020 compared to those in 2020.
Association between daily use of tobacco and cannabis and mental health outcomes.
Table 3 presents the associations between daily use of tobacco and cannabis products and anxiety and depression. Compared to non-daily use, daily use of cigarettes (Anxiety: OR 1.42, 95% CI 1.24–1.61; Depression: OR 1.41, 95% CI 1.24–1.60) and e-cigarettes (Anxiety: OR 1.47, 95% CI 1.25–1.74; Depression: OR 1.59, 95% CI 1.34–1.87) were associated with higher odds of both anxiety and depression. However, the associations between daily use of other combustible tobacco products and the mental health outcomes were not statistically significant. Daily use of cannabis (vs. non-daily use) was associated with higher odds of anxiety (OR 1.82, 95% CI 1.58–2.10) and depression (OR 1.68, 95% CI 1.46–1.95).
Results of the sensitivity analyses were very similar to those of the primary analyses. Compared to non-use, co-use was associated with the highest scores of GAD-7 and PHQ-8, followed by cannabis-only use, and tobacco-only use (S1 Table). Co-use and cannabis-only were associated with higher scores for GAD-7 and PHQ-8 than tobacco-only use. However, co-use was associated with higher scores of GAD-7 and PHQ-8 than cannabis-only use. Regarding dose-response relationships, greater frequency of using cigarettes, e-cigarettes, and cannabis were associated with higher scores of GAD-7 and PHQ-8 (S2 Table).
Discussion
Principal results
This study examined the extent to which different patterns of tobacco and cannabis use are associated with mental health disorders among US adults enrolled in a digital cohort study. As hypothesized, we found that use of tobacco and/or cannabis was positively associated with self-reported anxiety and depression. Notably, co-use was associated with higher odds of anxiety when compared to tobacco-only use, but not different from cannabis-only use. We also found that daily use of cigarettes, e-cigarettes, and cannabis were associated with the increased odds of reporting anxiety and depression. To our knowledge, this is the first study among the US adult population to evaluate the association of mental health with four mutually exclusive patterns of tobacco and cannabis use, with a focus on co-use of both substances.
Comparison with prior work
Consistent with prior studies [22,30], our study found that using tobacco alone and using cannabis alone were associated with higher odds of mental health disorders. Our study further extends the literature by indicating a graded effect size, ranging from lowest for tobacco-only, cannabis-only, to highest for co-use when comparing to non-use. This finding suggests both independent effects of tobacco and cannabis and joint effects of both substances on mental health. However, we could not determine causation of these associations due to the lack of data on initiation of tobacco and cannabis use as well as temporal onset of anxiety and depression. Current literature on this area is mixed, and accumulating evidence supports a bidirectional relationship between use of tobacco and cannabis and mental health [14]. Three mechanisms are proposed to explain the relationship between substance use and mental health, which could also be employed to explain our observed associations between use of tobacco and/or cannabis and anxiety and depression. These mechanisms are: (1) the self-medication or coping mechanism (using tobacco/cannabis to self-regulate and mitigate anxiety and depressive symptoms); (2) the substance-induced mechanism (use of tobacco and cannabis leads to a toxic effect and neurological changes that prompt or exacerbate anxiety and depressive symptoms, particularly during periods of acute or prolonged withdrawal); and (3) the shared-vulnerability mechanism (common genetic, behavioral, and environmental factors that predispose individuals to both substance use and mental health problems) [14]. Future work utilizing longitudinal research designs is needed to elucidate whether causal pathways differ for patterns of tobacco and cannabis use in the relationship with mental health disorders, ultimately informing prevention and treatment efforts.
Compared to single substance use, the odds of anxiety for co-use were higher than those for tobacco-only use, but were not significantly different from cannabis-only use. While these findings are suggestive of an additive effect of cannabis use on mental health among people who use tobacco, an additive effect of tobacco use among those who use cannabis use was not certain. This may be related to the large proportion of cannabis-only use in our sample. Indeed, 80.6% of our participants with past 30-day cannabis use reported using cannabis-only, while this proportion was only 8.4% in a population-based sample [39]. It should be noted that in our sensitivity analysis, co-use was significantly associated with higher scores of GAD-7 and PHQ-8 than cannabis-only use. Future studies are needed to confirm the robustness of our findings in other samples.
In addition, we found that lower frequency of physical activity was associated with higher odds of anxiety and depression. A review indicates that both tobacco use and low physical activity are lifestyle risk factors for mental health [40]. It should be noted that physical activity could be also a mediator in the relationship between substance use and mental health since people who use tobacco or cannabis may engage in less physical activity, which in turn results in poorer mental health. Given this study focused on the association between co-use and mental health, we adjusted for physical activity as a covariate in the multivariate models, and did not examine a potential meditating effect of physical activity. Future research should explore potential pathways through which multiple lifestyle factors may influence mental health outcomes.
As this study is conducted from early (2020) to later periods (2022) in the COVID-19 pandemic, we also found that the odds of reporting anxiety and depression were lower in later years than in 2020. This finding could be partly explained by unprecedented stress, economic hardship, lockdowns, and social isolation early in the pandemic [41,42].
Study implications
Our study has implications for clinical practice and public health efforts. The observed associations between use of tobacco and/or cannabis and anxiety and depression call for more attention to the comorbidity of substance use and mental health. This comorbidity is particularly concerning among those who use both tobacco and cannabis. Increased vulnerability to poor mental health in the co-use group may impede successful cessation from tobacco and cannabis [27]. Furthermore, co-use is common in low socioeconomic and sexual minority subpopulations, and thus, could exacerbate health disparities related to tobacco and cannabis use [43,44]. In addition to use of tobacco and/or cannabis, we also found that greater alcohol consumption was associated with higher odds of anxiety. Alcohol is frequently used with tobacco and cannabis and hazardous drinking is more prevalent among people with co-use compared to those with single substance use [45]. Polysubstance use may compromise the success of cessation from tobacco and cannabis [46]. As such, our study highlights a need for providing mental health support and addressing polysubstance use issues among people with co-use of tobacco and cannabis.
As tobacco and cannabis use are common among people with mental health issues, screening for use of tobacco and cannabis should be a priority in mental health treatment settings. In California, universal screening for tobacco use in substance use treatment settings was signed into law in 2021 [47]. In regards to treatment, our study suggests that coordinating tobacco and cannabis cessation with mental health treatment may be beneficial. Specifically, providing alternative coping strategies to reduce depressive and anxiety symptoms may be beneficial to people with use of tobacco and/or cannabis. A systematic review found that adding psychosocial mood management to usual smoking cessation treatment for people with current and historical depression increased smoking abstinence [48]. Similarly, counseling to support tobacco and cannabis cessation may improve mental health [49,50]. Indeed, another systematic review and meta-analysis showed that smoking cessation is associated with reduced anxiety, depression, and stress and improved mood and quality of life [51]. As we found that daily use of tobacco and cannabis is associated with higher odds of anxiety and depression, cessation services for people with mental health disorders should be tailored to address heavy use and dependence of nicotine and cannabis.
Furthermore, despite insufficient evidence regarding therapeutic benefits of cannabis, nearly half of US adults view cannabis as self-medication for treating depression and anxiety symptoms [52]. Similarly, many people, especially young adults, misinterpret nicotine as helping to relieve stress, anxiety, and depression [53]. To correct these misperceptions, public health campaigns should highlight potential negative effects of tobacco and cannabis use on mental health.
Limitations
This study has several limitations. As aforementioned, the causal relationships between patterns of tobacco and cannabis use and mental health disorders cannot be elucidated given the study design. Since use of tobacco and cannabis was measured only once at baseline, we could not examine potential effects of changes in substance use on mental health. Longitudinal studies using repeated measures of both substance use and mental health over time are needed to uncover causal and dynamic relationships. Our digital cohort recruited via a convenience sampling method which, although allowing for a large sample size and facilitating data collection during the COVID-19 pandemic, may limit the findings’ generalizability. Since our sample is not a nationally representative population-based sample, cautions should be taken in interpreting the findings to other samples. Of note, we only asked about use of combustible or vaporized cannabis products, and thus, findings may not generalize to other modes of consumption. Self-reported data and non-respondents may be subject to bias. Data on nicotine and cannabis dependence and the purpose of cannabis use (e.g., recreational or medicinal cannabis use) were not collected; thus, we could not examine potential impacts of these factors on mental health.
Conclusions
This study provided recent data on positive associations of the mutually exclusive patterns of tobacco and cannabis use with mental health, with a focus on co-use of both substances among US adults. Co-use of tobacco and cannabis and use of cannabis-only were associated with higher odds of anxiety and depression compared to non-use and tobacco-only use. Tobacco-only use was associated with higher odds of anxiety and depression compared to non-use. The findings suggest that coordinating tobacco and cannabis cessation with mental health treatment may be beneficial to address these comorbidities. Specifically, providing mental health support and addressing polysubstance use (e.g., tobacco, cannabis, alcohol) among individuals with co-use are needed to facilitate successful cessation from tobacco and cannabis.
Supporting information
S1 Table. Comparisons of GAD-7 and PHQ-8 scores between patterns of tobacco and cannabis use.
https://doi.org/10.1371/journal.pone.0289058.s001
(DOCX)
S2 Table. Dose-response relationship between frequency of use of tobacco and cannabis products with GAD-7 and PHQ-8 scores.
https://doi.org/10.1371/journal.pone.0289058.s002
(DOCX)
References
- 1.
SAMHSA C for BHS and Q. National Survey on Drug Use and Health (NSDUH) [Internet]. 2020. https://www.samhsa.gov/data/report/2020-nsduh-detailed-tables.
- 2. Cohn AM, Chen S. Age groups differences in the prevalence and popularity of individual tobacco product use in young adult and adult marijuana and tobacco co-users and tobacco-only users: Findings from Wave 4 of the population assessment of tobacco and health study. Drug Alcohol Depend. 2022 Apr 1;233:109278. pmid:35151023
- 3. Weinberger AH, Wyka K, Goodwin RD. Impact of cannabis legalization in the United States on trends in cannabis use and daily cannabis use among individuals who smoke cigarettes. Drug Alcohol Depend. 2022 Sep 1;238:109563. pmid:35870333
- 4. Cerdá M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, et al. Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016. JAMA Psychiatry. 2020 Feb 1;77(2):165. pmid:31722000
- 5. Hindocha C, McClure EA. Unknown population-level harms of cannabis and tobacco co-use: if you don’t measure it, you can’t manage it. Addiction. 2021;116(7):1622–30. pmid:33047862
- 6. Meier E, Hatsukami DK. A review of the additive health risk of cannabis and tobacco co-use. Drug Alcohol Depend. 2016 Sep 1;166:6–12. pmid:27476751
- 7. Rabin RA, George TP. A review of co-morbid tobacco and cannabis use disorders: possible mechanisms to explain high rates of co-use. Am J Addict. 2015 Mar;24(2):105–16. pmid:25662704
- 8. Weinberger AH, Pacek LR, Wall MM, Gbedemah M, Lee J, Goodwin RD. Cigarette smoking quit ratios among adults in the USA with cannabis use and cannabis use disorders, 2002–2016. Tob Control. 2020 Jan;29(1):74–80. pmid:30952691
- 9. Driezen P, Gravely S, Wadsworth E, Smith DM, Loewen R, Hammond D, et al. Increasing Cannabis Use Is Associated With Poorer Cigarette Smoking Cessation Outcomes: Findings From the ITC Four Country Smoking and Vaping Surveys, 2016–2018. Nicotine Tob Res. 2021 Jun 10;24(1):53–9.
- 10. Ream GL, Benoit E, Johnson BD, Dunlap E. Smoking tobacco along with marijuana increases symptoms of cannabis dependence. Drug Alcohol Depend. 2008 Jun 1;95(3):199–208. pmid:18339491
- 11. Nguyen N, Nguyen C, Thrul J. Digital Health for Assessment and Intervention Targeting Tobacco and Cannabis Co-Use. Curr Addict Rep [Internet]. 2020 Jun 19 [cited 2020 Aug 19]; pmid:33643768
- 12. Prochaska JJ, Das S, Young-Wolff KC. Smoking, Mental Illness, and Public Health. Annu Rev Public Health. 2017 Mar 20;38:165–85. pmid:27992725
- 13. Lowe DJE, Sasiadek JD, Coles AS, George TP. Cannabis and Mental Illness: A Review. Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):107–20. pmid:30564886
- 14. Garey L, Olofsson H, Garza T, Rogers AH, Kauffman BY, Zvolensky MJ. Directional Effects of Anxiety and Depressive Disorders with Substance Use: a Review of Recent Prospective Research. Curr Addict Rep. 2020 Sep 1;7(3):344–55.
- 15. Fluharty M, Taylor AE, Grabski M, Munafò MR. The Association of Cigarette Smoking With Depression and Anxiety: A Systematic Review. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2017 Jan;19(1):3–13. pmid:27199385
- 16. Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ. Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiatr Res. 2015 Aug;66–67:135–41. pmid:26022838
- 17. Bakhshaie J, Zvolensky MJ, Goodwin RD. Cigarette smoking and the onset and persistence of depression among adults in the United States: 1994–2005. Compr Psychiatry. 2015 Jul;60:142–8. pmid:25882595
- 18. Nguyen HV, Mital S. Effects of e-cigarette use on mental health among youths: quasi-experimental evidence from Canada. Addict Abingdon Engl. 2022 Oct;117(10):2673–82. pmid:35545859
- 19. Weinberger AH, Chaiton MO, Zhu J, Wall MM, Hasin DS, Goodwin RD. Trends in the Prevalence of Current, Daily, and Nondaily Cigarette Smoking and Quit Ratios by Depression Status in the U.S.: 2005–2017. Am J Prev Med. 2020 May 1;58(5):691–8. pmid:32156490
- 20. Marsden DG, Loukas A, Chen B, Perry CL, Wilkinson AV. Associations between frequency of cigarette and alternative tobacco product use and depressive symptoms: A longitudinal study of young adults. Addict Behav. 2019 Dec 1;99:106078. pmid:31430619
- 21. Obisesan OH, Mirbolouk M, Osei AD, Orimoloye OA, Uddin SMI, Dzaye O, et al. Association Between e-Cigarette Use and Depression in the Behavioral Risk Factor Surveillance System, 2016–2017. JAMA Netw Open. 2019 Dec 4;2(12):e1916800. pmid:31800073
- 22. Gorfinkel LR, Stohl M, Hasin D. Association of Depression With Past-Month Cannabis Use Among US Adults Aged 20 to 59 Years, 2005 to 2016. JAMA Netw Open. 2020 Aug 18;3(8):e2013802. pmid:32809032
- 23. Pacek LR, Weinberger AH, Zhu J, Goodwin RD. Rapid increase in the prevalence of cannabis use among people with depression in the United States, 2005–17: the role of differentially changing risk perceptions. Addict Abingdon Engl. 2020 May;115(5):935–43. pmid:31797462
- 24. Weinberger AH, Zhu J, Levin J, Barrington-Trimis JL, Copeland J, Wyka K, et al. Cannabis use among US adults with anxiety from 2008 to 2017: The role of state-level cannabis legalization. Drug Alcohol Depend. 2020 Sep 1;214:108163. pmid:32707516
- 25. Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse Health Effects of Marijuana Use. N Engl J Med. 2014 Jun 5;370(23):2219–27. pmid:24897085
- 26. Gobbi G, Atkin T, Zytynski T, Wang S, Askari S, Boruff J, et al. Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019 Apr 1;76(4):426–34. pmid:30758486
- 27. McClave AK, Dube SR, Strine TW, Kroenke K, Caraballo RS, Mokdad AH. Associations between smoking cessation and anxiety and depression among U.S. adults. Addict Behav. 2009 Jun 1;34(6):491–7. pmid:19217720
- 28. Onaemo VN, Fawehinmi TO, D’Arcy C. Comorbid Cannabis Use Disorder with Major Depression and Generalized Anxiety Disorder: A Systematic Review with Meta-analysis of Nationally Representative Epidemiological Surveys. J Affect Disord. 2021 Feb 15;281:467–75. pmid:33360749
- 29. Hindocha C, Brose LS, Walsh H, Cheeseman H. Cannabis use and co-use in tobacco smokers and non-smokers: prevalence and associations with mental health in a cross-sectional, nationally representative sample of adults in Great Britain, 2020. Addict Abingdon Engl. 2021 Aug;116(8):2209–19.
- 30. Gravely S, Driezen P, McClure EA, Hammond D, Michael Cummings K, Chan G, et al. Differences between adults who smoke cigarettes daily and do and do not co-use cannabis: Findings from the 2020 ITC four country smoking and vaping survey. Addict Behav. 2022 Dec;135:107434. pmid:35908323
- 31. Peters EN, Schwartz RP, Wang S, O’Grady KE, Blanco C. Psychiatric, psychosocial, and physical health correlates of co-occurring cannabis use disorders and nicotine dependence. Drug Alcohol Depend. 2014 Jan 1;134:228–34. pmid:24183498
- 32. Beatty AL, Peyser ND, Butcher XE, Carton TW, Olgin JE, Pletcher MJ, et al. The COVID-19 Citizen Science Study: Protocol for a Longitudinal Digital Health Cohort Study. JMIR Res Protoc. 2021 Aug 30;10(8):e28169. pmid:34310336
- 33. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7. Arch Intern Med. 2006 May 22;166(10):1092–7. pmid:16717171
- 34. Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009 Apr 1;114(1):163–73. pmid:18752852
- 35. Adler NE, Epel ES, Castellazzo G, Ickovics JR. Relationship of subjective and objective social status with psychological and physiological functioning: preliminary data in healthy white women. Health Psychol Off J Div Health Psychol Am Psychol Assoc. 2000 Nov;19(6):586–92. pmid:11129362
- 36. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988 Dec;44(4):1049–60. pmid:3233245
- 37. Ettman CK, Abdalla SM, Cohen GH, Sampson L, Vivier PM, Galea S. Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Netw Open. 2020 Sep 2;3(9):e2019686. pmid:32876685
- 38. Robinson E, Sutin AR, Daly M, Jones A. A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic in 2020. J Affect Disord. 2022 Jan 1;296:567–76. pmid:34600966
- 39. Carlini BH, Schauer GL. Cannabis-only use in the USA: prevalence, demographics, use patterns, and health indicators. J Cannabis Res. 2022 Jul 22;4(1):39. pmid:35864553
- 40. Firth J, Solmi M, Wootton RE, Vancampfort D, Schuch FB, Hoare E, et al. A meta-review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. World Psychiatry. 2020;19(3):360–80. pmid:32931092
- 41. Killgore WDS, Cloonan SA, Taylor EC, Dailey NS. Mental Health During the First Weeks of the COVID-19 Pandemic in the United States. Front Psychiatry [Internet]. 2021 [cited 2023 May 25];12. https://www.frontiersin.org/articles/10.3389/fpsyt.2021.561898 pmid:33967841
- 42. Holmes EA, O’Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry. 2020 Jun 1;7(6):547–60. pmid:32304649
- 43. McRobbie H, Boland VC, Courtney RJ. Assessing cannabis and tobacco co-use: the pros and cons of additional data collection. Addiction. 2021;116(7):1631–3. pmid:33417256
- 44. Nguyen N, McQuoid J, Neilands TB, Dermody SS, Holmes LM, Ling PM, et al. Same-day use of cigarettes, alcohol, and cannabis among sexual minority and heterosexual young adult smokers. Psychol Addict Behav J Soc Psychol Addict Behav. 2021 Mar;35(2):215–23. pmid:32804517
- 45. Schauer GL, Peters EN. Correlates and trends in youth co-use of marijuana and tobacco in the United States, 2005–2014. Drug Alcohol Depend. 2018 Apr 1;185:238–44. pmid:29471228
- 46. Lim CCW, Leung JKY, Gravely S, Gartner C, Sun T, Chiu V, et al. A latent class analysis of patterns of tobacco and cannabis use in Australia and their health-related correlates. Drug Alcohol Rev. 2023 May;42(4):815–26. pmid:36780230
- 47.
Assembly Bill No. 541 [Internet]. https://leginfo.legislature.ca.gov/faces/billTextClient.xhtml?bill_id=202120220AB541
- 48. van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev. 2013 Aug 21;(8):CD006102. pmid:23963776
- 49. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014 Feb 13;348:g1151. pmid:24524926
- 50. Mooney LJ, Zhu Y, Yoo C, Valdez J, Moino K, Liao JY, et al. Reduction in Cannabis Use and Functional Status in Physical Health, Mental Health, and Cognition. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. 2018 Dec;13(4):479–87. pmid:30284156
- 51. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014 Feb 13;348:g1151. pmid:24524926
- 52. Keyhani S, Steigerwald S, Ishida J, Vali M, Cerdá M, Hasin D, et al. Risks and Benefits of Marijuana Use: A National Survey of U.S. Adults. Ann Intern Med. 2018 4;169(5):282–90. pmid:30039154
- 53.
Truth Initiative. Colliding Crises: Youth Mental Health and Nicotine Use. 2021.